About: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) հոդված (hy) wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 2007 (uk) im März 2007 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q58023972-587B2226-3E92-4031-A214-B624891FC587
publication date	2007-04-03 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58023972-A7249DC3-F9D0-4125-83E4-D0D95C9ED346
language of work or name	English
author name string	wds:Q58023972-20C13736-F11C-4945-94A1-53554FDBBE52 wds:Q58023972-2B5F7B3F-1424-4D47-ABE3-306E4ED8A2E1 wds:Q58023972-553678B2-1BAB-470C-97E4-6D17FF0B0AC9 wds:Q58023972-5EADA7F3-6B36-4903-9DEB-4A23DC95C17F wds:Q58023972-6045C5E4-8A4A-42AF-8B4C-4DFE4751EB2D wds:Q58023972-9E90279B-A371-42F0-ABF9-204EB2A585A1 wds:Q58023972-CADDBE3E-B65C-45CC-890B-2F3E2E38FB19 wds:Q58023972-DBE27F07-DDC3-40B4-87FE-531A5B2E6D1E wds:Q58023972-DC22B44C-FF7D-4C34-93F7-61B4F0029E67 wds:Q58023972-DE6C9DBA-8811-4B00-9FCE-CF89F234446D
author name string	Anna Pavlova Johannes Oldenburg Dieter Hoelzer Thoralf Lange Heike Pfeifer Barbara Wassmann Anja Binckebanck Lydia Wunderle Patrick Brück Silvia Wystub
rdfs:label	Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) (en) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (nl)
skos:prefLabel	Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) (en) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (nl)
name	Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) (en) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (nl)
author	wds:Q58023972-8810F931-BE92-42DB-BACE-A7CDB34CF93D wds:Q58023972-A20A1295-6951-4A12-AB20-C56086000B36
author	Andreas Hochhaus Oliver Ottmann
title	wds:Q58023972-EB163D77-D927-4841-A76A-CBC1A722AB45
title	Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) (en)
page(s)	wds:Q58023972-6DD005C0-1A9C-402C-9A29-3CCDD1D8B1E2
page(s)	727-734
instance of	wds:Q58023972-6091F3E4-7177-4A99-AFDB-5BFB0D8D6E91
instance of	scholarly article
main subject	wds:Q58023972-03F61959-4670-4603-8DC2-CA33CA44A1B8 wds:Q58023972-0E815FDD-F169-49BC-A578-31EE80F125F4 wds:Q58023972-26B110FF-E209-4F6F-A8B1-F1B015E92A55
main subject	leukemia Patients lymphoblastic leukemia
PubMed ID	wds:Q58023972-B97BA1C4-AF6E-44BF-A43E-3D60F35FA3C7
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17405907
PubMed ID	17405907
published in	wds:Q58023972-FCACB799-766C-4407-BCE7-78A534CB9438
published in	Blood
issue	wds:Q58023972-2C825B90-28FF-42FE-BBA5-36B13C4BFACF
volume	wds:Q58023972-6D11419B-2E4E-4D78-BD2A-03DCFE09300D
issue	2
volume	110
DOI	wds:Q58023972-F19F780C-3BC5-4B8B-95B7-34D8FF76EEBB
DOI	http://dx.doi.org/10.1182/BLOOD-2006-11-052373
DOI	10.1182/BLOOD-2006-11-052373
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58023972
is cites work of	A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia Clonal competition with alternating dominance in multiple myeloma. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia Activation of tyrosine kinases by mutation of the gatekeeper threonine Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors Sunitinib rechallenge in metastatic renal cell carcinoma patients First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients Current and future management of Ph/BCR-ABL positive ALL. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia Philadelphia-positive acute lymphoblastic leukemia: current treatment options Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Evolutionary determinants of cancer Genomic instability in chronic myeloid leukemia: targets for therapy? Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia Philadelphia chromosome-positive acute lymphoblastic leukemia Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software